Abstract
A case story is presented, describing a 46 y old man, with a relapsing hairy cell leukaemia. After treatment with monoclonal anti CD-20 antibodies (rituximab) 375 mg/week, four times, a complete remission was obtained which has lasted >9 months. The rituximab treatment produced a better remission than earlier treatments with alpha-interferon and chlorodeoxyadenosine. In addition, in contrast to other treatments, no initial worsening of the pancytopenia was observed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cheson BDet al. Treatment of hairy cell leukemia with 2 chlorodeoxyadenosine via the group C protocol mechanism of the National Cancer Institute: A report of 979 patients.J Clin Oncol 1998;16: 3007–3015.
McLaughlin Pet al.. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of the patients respond to a four-dose treatment program.J Clin Oncol 1998;16: 2825–2833.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hagberg, H. Chimeric monoclonal anti-CD20 antibody (rituximab)—an effective treatment for a patient with relapsing hairy cell leukaemia. Med Oncol 16, 221–222 (1999). https://doi.org/10.1007/BF02906136
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02906136